SAT0125 The impact of selected comorbidities on treatment outcome in patients with rheumatoid arthritis: an exploratory cohort study.

Amir Emamifar, Inger Marie Jensen Hansen

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

Resumé

Background: Patients with Rheumatoid Arthritis (RA) may present with various comorbidities resulting in worse treatment response.[1-2] Objectives: To investigate the impact of selected comorbid diseases on RA outcome with the aim of Disease Activity Score in 28 joints-C-Reactive Protein (DAS28-CRP). Methods: All our RA patients were included in this study. Patients’ demographics, serology results and DAS28-CRP at the time of diagnosis and after 4 months of treatment initiation were collected. Patients’ electronic hospital records were evaluated for a positive history of thyroid diseases, Diabetes Mellitus (DM), primary hyperparathyroidism, vitamin B12 deficiency and presence of other diagnosed autoimmune diseases. Results: 1035 RA patients were included. 63.4% were female, mean of age 67.1 years, mean of disease duration 9.6 years, 58.6% rheumatoid factor positive and 51.3% anti-cyclic citrullinated peptide positive. The observed prevalence of thyroid diseases was 11.8%, DM 10.4%, primary hyperparathyroidism 2.8%, vitamin B12 deficiency 5.8%, and other diagnosed autoimmune diseases 1.6%. There were significant associations between presence of thyroid diseases and female gender (p<0.001); DM and greater age (p<0.001); primary hyperparathyroidism and longer disease duration (p=0.002); other diagnosed autoimmune diseases and antinuclear antibody positivity (p<0.001). RA patients with thyroid diseases (p=0.001) and other comorbid autoimmune diseases (p<0.001) had significantly poorer initial response to the RA treatment compared to patients with isolated RA. Univariate analyses revealed that age, presence of thyroid diseases, presence of other diagnosed autoimmune diseases and DAS28-CRP at the time of diagnosis were significantly associated with ΔDAS28-CRP. Additionally, multivariate analysis demonstrated that ΔDAS28-CRP deterioration was significantly correlated to the presence of thyroid diseases (unstandardized regression coefficient (standard error);-0.188(0.088),p=0.030) and presence of other diagnosed autoimmune diseases (-0.537(0.208),p=0.010). (table1) Conclusions: RA patients are at increased risk of specific comorbidities with possible impact on the treatment outcome. The authors, therefore, recommend to do periodical assessment of comorbidities to diagnose concurrent comorbid diseases as early as possible. REFERENCES: [1] Emamifar A, et al. Thyroid disorders in patients with newly diagnosed rheumatoid arthritis is associated with poor initial treatment response evaluated by disease activity score in 28 joints-C-reactive protein (DAS28- CRP): An observational cohort study. Medicine (Baltimore) 2017;96:e8357. [2] Emamifar A, et al. Patients with newly diagnosed Rheumatoid Arthritis are at increased risk of Diabetes Mellitus: An Observational Cohort study. Acta Reumatol Port 2017 [Epub ahead of print].
OriginalsprogEngelsk
Publikationsdato16. jun. 2018
Antal sider2
StatusUdgivet - 16. jun. 2018
BegivenhedEULAR 2018 - Amsterdam, Holland
Varighed: 13. jun. 201816. jun. 2018

Konference

KonferenceEULAR 2018
LandHolland
ByAmsterdam
Periode13/06/201816/06/2018

Fingeraftryk

Comorbidity
Cohort Studies
Joints
Primary Hyperparathyroidism
Diabetes Mellitus
Baltimore
Hospital Records
Rheumatoid Factor
Serology
Multivariate Analysis
Medicine

Citer dette

Emamifar, A., & Jensen Hansen, I. M. (2018). SAT0125 The impact of selected comorbidities on treatment outcome in patients with rheumatoid arthritis: an exploratory cohort study.. 924-925. Poster session præsenteret på EULAR 2018, Amsterdam, Holland.
Emamifar, Amir ; Jensen Hansen, Inger Marie. / SAT0125 The impact of selected comorbidities on treatment outcome in patients with rheumatoid arthritis: an exploratory cohort study. Poster session præsenteret på EULAR 2018, Amsterdam, Holland.2 s.
@conference{1ba5eec60006434c8a41a2b90159725d,
title = "SAT0125 The impact of selected comorbidities on treatment outcome in patients with rheumatoid arthritis: an exploratory cohort study.",
abstract = "Background: Patients with Rheumatoid Arthritis (RA) may present with various comorbidities resulting in worse treatment response.[1-2] Objectives: To investigate the impact of selected comorbid diseases on RA outcome with the aim of Disease Activity Score in 28 joints-C-Reactive Protein (DAS28-CRP). Methods: All our RA patients were included in this study. Patients’ demographics, serology results and DAS28-CRP at the time of diagnosis and after 4 months of treatment initiation were collected. Patients’ electronic hospital records were evaluated for a positive history of thyroid diseases, Diabetes Mellitus (DM), primary hyperparathyroidism, vitamin B12 deficiency and presence of other diagnosed autoimmune diseases. Results: 1035 RA patients were included. 63.4{\%} were female, mean of age 67.1 years, mean of disease duration 9.6 years, 58.6{\%} rheumatoid factor positive and 51.3{\%} anti-cyclic citrullinated peptide positive. The observed prevalence of thyroid diseases was 11.8{\%}, DM 10.4{\%}, primary hyperparathyroidism 2.8{\%}, vitamin B12 deficiency 5.8{\%}, and other diagnosed autoimmune diseases 1.6{\%}. There were significant associations between presence of thyroid diseases and female gender (p<0.001); DM and greater age (p<0.001); primary hyperparathyroidism and longer disease duration (p=0.002); other diagnosed autoimmune diseases and antinuclear antibody positivity (p<0.001). RA patients with thyroid diseases (p=0.001) and other comorbid autoimmune diseases (p<0.001) had significantly poorer initial response to the RA treatment compared to patients with isolated RA. Univariate analyses revealed that age, presence of thyroid diseases, presence of other diagnosed autoimmune diseases and DAS28-CRP at the time of diagnosis were significantly associated with ΔDAS28-CRP. Additionally, multivariate analysis demonstrated that ΔDAS28-CRP deterioration was significantly correlated to the presence of thyroid diseases (unstandardized regression coefficient (standard error);-0.188(0.088),p=0.030) and presence of other diagnosed autoimmune diseases (-0.537(0.208),p=0.010). (table1) Conclusions: RA patients are at increased risk of specific comorbidities with possible impact on the treatment outcome. The authors, therefore, recommend to do periodical assessment of comorbidities to diagnose concurrent comorbid diseases as early as possible. REFERENCES: [1] Emamifar A, et al. Thyroid disorders in patients with newly diagnosed rheumatoid arthritis is associated with poor initial treatment response evaluated by disease activity score in 28 joints-C-reactive protein (DAS28- CRP): An observational cohort study. Medicine (Baltimore) 2017;96:e8357. [2] Emamifar A, et al. Patients with newly diagnosed Rheumatoid Arthritis are at increased risk of Diabetes Mellitus: An Observational Cohort study. Acta Reumatol Port 2017 [Epub ahead of print].",
author = "Amir Emamifar and {Jensen Hansen}, {Inger Marie}",
year = "2018",
month = "6",
day = "16",
language = "English",
pages = "924--925",
note = "null ; Conference date: 13-06-2018 Through 16-06-2018",

}

Emamifar, A & Jensen Hansen, IM 2018, 'SAT0125 The impact of selected comorbidities on treatment outcome in patients with rheumatoid arthritis: an exploratory cohort study.', EULAR 2018, Amsterdam, Holland, 13/06/2018 - 16/06/2018 s. 924-925.

SAT0125 The impact of selected comorbidities on treatment outcome in patients with rheumatoid arthritis: an exploratory cohort study. / Emamifar, Amir; Jensen Hansen, Inger Marie.

2018. 924-925 Poster session præsenteret på EULAR 2018, Amsterdam, Holland.

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

TY - CONF

T1 - SAT0125 The impact of selected comorbidities on treatment outcome in patients with rheumatoid arthritis: an exploratory cohort study.

AU - Emamifar, Amir

AU - Jensen Hansen, Inger Marie

PY - 2018/6/16

Y1 - 2018/6/16

N2 - Background: Patients with Rheumatoid Arthritis (RA) may present with various comorbidities resulting in worse treatment response.[1-2] Objectives: To investigate the impact of selected comorbid diseases on RA outcome with the aim of Disease Activity Score in 28 joints-C-Reactive Protein (DAS28-CRP). Methods: All our RA patients were included in this study. Patients’ demographics, serology results and DAS28-CRP at the time of diagnosis and after 4 months of treatment initiation were collected. Patients’ electronic hospital records were evaluated for a positive history of thyroid diseases, Diabetes Mellitus (DM), primary hyperparathyroidism, vitamin B12 deficiency and presence of other diagnosed autoimmune diseases. Results: 1035 RA patients were included. 63.4% were female, mean of age 67.1 years, mean of disease duration 9.6 years, 58.6% rheumatoid factor positive and 51.3% anti-cyclic citrullinated peptide positive. The observed prevalence of thyroid diseases was 11.8%, DM 10.4%, primary hyperparathyroidism 2.8%, vitamin B12 deficiency 5.8%, and other diagnosed autoimmune diseases 1.6%. There were significant associations between presence of thyroid diseases and female gender (p<0.001); DM and greater age (p<0.001); primary hyperparathyroidism and longer disease duration (p=0.002); other diagnosed autoimmune diseases and antinuclear antibody positivity (p<0.001). RA patients with thyroid diseases (p=0.001) and other comorbid autoimmune diseases (p<0.001) had significantly poorer initial response to the RA treatment compared to patients with isolated RA. Univariate analyses revealed that age, presence of thyroid diseases, presence of other diagnosed autoimmune diseases and DAS28-CRP at the time of diagnosis were significantly associated with ΔDAS28-CRP. Additionally, multivariate analysis demonstrated that ΔDAS28-CRP deterioration was significantly correlated to the presence of thyroid diseases (unstandardized regression coefficient (standard error);-0.188(0.088),p=0.030) and presence of other diagnosed autoimmune diseases (-0.537(0.208),p=0.010). (table1) Conclusions: RA patients are at increased risk of specific comorbidities with possible impact on the treatment outcome. The authors, therefore, recommend to do periodical assessment of comorbidities to diagnose concurrent comorbid diseases as early as possible. REFERENCES: [1] Emamifar A, et al. Thyroid disorders in patients with newly diagnosed rheumatoid arthritis is associated with poor initial treatment response evaluated by disease activity score in 28 joints-C-reactive protein (DAS28- CRP): An observational cohort study. Medicine (Baltimore) 2017;96:e8357. [2] Emamifar A, et al. Patients with newly diagnosed Rheumatoid Arthritis are at increased risk of Diabetes Mellitus: An Observational Cohort study. Acta Reumatol Port 2017 [Epub ahead of print].

AB - Background: Patients with Rheumatoid Arthritis (RA) may present with various comorbidities resulting in worse treatment response.[1-2] Objectives: To investigate the impact of selected comorbid diseases on RA outcome with the aim of Disease Activity Score in 28 joints-C-Reactive Protein (DAS28-CRP). Methods: All our RA patients were included in this study. Patients’ demographics, serology results and DAS28-CRP at the time of diagnosis and after 4 months of treatment initiation were collected. Patients’ electronic hospital records were evaluated for a positive history of thyroid diseases, Diabetes Mellitus (DM), primary hyperparathyroidism, vitamin B12 deficiency and presence of other diagnosed autoimmune diseases. Results: 1035 RA patients were included. 63.4% were female, mean of age 67.1 years, mean of disease duration 9.6 years, 58.6% rheumatoid factor positive and 51.3% anti-cyclic citrullinated peptide positive. The observed prevalence of thyroid diseases was 11.8%, DM 10.4%, primary hyperparathyroidism 2.8%, vitamin B12 deficiency 5.8%, and other diagnosed autoimmune diseases 1.6%. There were significant associations between presence of thyroid diseases and female gender (p<0.001); DM and greater age (p<0.001); primary hyperparathyroidism and longer disease duration (p=0.002); other diagnosed autoimmune diseases and antinuclear antibody positivity (p<0.001). RA patients with thyroid diseases (p=0.001) and other comorbid autoimmune diseases (p<0.001) had significantly poorer initial response to the RA treatment compared to patients with isolated RA. Univariate analyses revealed that age, presence of thyroid diseases, presence of other diagnosed autoimmune diseases and DAS28-CRP at the time of diagnosis were significantly associated with ΔDAS28-CRP. Additionally, multivariate analysis demonstrated that ΔDAS28-CRP deterioration was significantly correlated to the presence of thyroid diseases (unstandardized regression coefficient (standard error);-0.188(0.088),p=0.030) and presence of other diagnosed autoimmune diseases (-0.537(0.208),p=0.010). (table1) Conclusions: RA patients are at increased risk of specific comorbidities with possible impact on the treatment outcome. The authors, therefore, recommend to do periodical assessment of comorbidities to diagnose concurrent comorbid diseases as early as possible. REFERENCES: [1] Emamifar A, et al. Thyroid disorders in patients with newly diagnosed rheumatoid arthritis is associated with poor initial treatment response evaluated by disease activity score in 28 joints-C-reactive protein (DAS28- CRP): An observational cohort study. Medicine (Baltimore) 2017;96:e8357. [2] Emamifar A, et al. Patients with newly diagnosed Rheumatoid Arthritis are at increased risk of Diabetes Mellitus: An Observational Cohort study. Acta Reumatol Port 2017 [Epub ahead of print].

M3 - Poster

SP - 924

EP - 925

ER -